Ángela Sánchez Juez

Ángela Sánchez Juez

Auto-generated profile, based on publicly available information

Ángela Sánchez Juez

Hospital-at-Home Unit, Hospital Universitario de La Princesa, Madrid, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2026 in European Journal of Internal Medicine
Verified
Journal Article
Open access
PRPablo Rodríguez-Cortés
Pablo Rodríguez-Cortés
ECElena Arranz Canales
Elena Arranz Canales
AÁAlexia Constanza Espiño Álvarez
Alexia Constanza Espiño Álvarez
JSJavier B. Pérez Serrano
Javier B. Pérez Serrano
LRLaura Rabes-Rodríguez
Laura Rabes-Rodríguez
FSFernando Sebastian-Valles
Fernando Sebastian-Valles

28 August 2026 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLira Pelari Mici
Lira Pelari Mici
ECElena Arranz Canales
Elena Arranz Canales
AÁAlexia Constanza Espiño Álvarez
Alexia Constanza Espiño Álvarez
EBEva María Fernández Bermejo
Eva María Fernández Bermejo
ÁJÁngela Sánchez Juez
Ángela Sánchez Juez
PRPablo Rodríguez-Cortés
Pablo Rodríguez-Cortés
Purpose: Complicated urinary tract infections (cUTIs) are a frequent indication for admission to Hospital-at-Home (HaH) and outpatient parenteral antimicrobial therapy (OPAT) programmes. We describe the clinical, urological and microbiological profile, antimicrobial treatment and outcomes of a cUTI cohort managed in a HaH unit, and explored, in an exploratory analysis, factors associated with the 30-day composite of unplanned readmission or death. Methods: Prospective observational single-centre cohort of 262 consecutive cUTI episodes managed in a tertiary HaH unit (March 2023-October 2025). Baseline, urological, microbiological, treatment and outcome variables were recorded prospectively. Bivariate comparisons and an exploratory multivariable logistic regression were used to examine associations with the composite endpoint. Results: Median age was 79.7 years (Q1-Q3 66.1–87.2); 76.0% had multimorbidity. Escherichia coli was the most frequent isolate (45.4%; 41.2% ESBL-producing, 95% CI 32.7–50.2%), and the overall rate of resistance-mechanism-positive isolates was 30.2% (95% CI 24.9–36.0%). Ertapenem (42.8%) and ceftriaxone (41.2%) were the most frequently used intravenous agents. Clinical cure occurred in 92.0% (95% CI 88.1–94.7%) of episodes and 5.3% (95% CI 3.2–8.8%) required unplanned transfer to conventional care, with no deaths during the HaH episode. Within 30 days, 11.5% of episodes (95% CI 8.1–15.9%) were followed by hospital readmission and 4.2% (95% CI 2.4–7.4%) by death (composite endpoint, 13.4%, 95% CI 9.8–18.0%). In exploratory, hypothesis-generating analyses limited by the small number of events, older age and prior urological manipulation were identified as potential factors associated with the composite endpoint (age: OR 1.05, 95% CI 1.01–1.10; prior urological manipulation: OR 2.98, 95% CI 1.12–7.98), with wide confidence intervals. Conclusion: In this single-centre, uncontrolled descriptive cohort, cUTI managed through HaH/OPAT was associated with high clinical cure and low unplanned transfer, despite a substantial burden of ESBL-producing organisms and other resistance-mechanism-positive isolates. Older age and prior urological manipulation emerged as potential markers associated with adverse outcomes, warranting further characterisation in larger, adequately powered cohorts before informing risk stratification at HaH admission.